Cargando…

Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer

OBJECTIVE: Neoadjuvant concomitant chemoradiotherapy followed by surgical resection is the standard of care in the treatment of rectal cancer. We are investigating the value of adding combination chemotherapy oxaliplatin, irinotecan, leucovorin and fluorouracil (FOLFIRINOX) before neoadjuvant chemor...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakr, Amr, Elsherbeiny, Mamdouh, Moneim, Rabab Abdel, Shaaban, Saeed, Aldaly, Moustafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568879/
https://www.ncbi.nlm.nih.gov/pubmed/32592369
http://dx.doi.org/10.31557/APJCP.2020.21.6.1717
_version_ 1783596612545675264
author Sakr, Amr
Elsherbeiny, Mamdouh
Moneim, Rabab Abdel
Shaaban, Saeed
Aldaly, Moustafa
author_facet Sakr, Amr
Elsherbeiny, Mamdouh
Moneim, Rabab Abdel
Shaaban, Saeed
Aldaly, Moustafa
author_sort Sakr, Amr
collection PubMed
description OBJECTIVE: Neoadjuvant concomitant chemoradiotherapy followed by surgical resection is the standard of care in the treatment of rectal cancer. We are investigating the value of adding combination chemotherapy oxaliplatin, irinotecan, leucovorin and fluorouracil (FOLFIRINOX) before neoadjuvant chemoradiotherapy. METHODS: Forty-one patients with middle and lower rectal cancer were included. FOLFORINOX were given every 2 weeks over 2 months (4 cycles) followed by concomitant chemoradiotherapy (CRT). Surgery was done 6-8 weeks after CRT and then adjuvant 4 months of FOLFOX or XELOX were given. The primary end point was sphincter preservation rate. RESULTS: All patients received the four cycles of neoadjuvant chemotherapy FOLFORINOX, 38 patients completed CRT and only 29 patients underwent surgery. 32 patients were available for assessment (29 patients who underwent surgery and three patients who refuse surgery because of no evidence of disease by endoscopy, imaging and biopsy). Sphincter preservation was achieved in twenty-one patients (51.2%). Pathological complete response rate was 24.1%. After a median follow up of 24 months. Median PFS was 20 months and 2-years PFS was 62.3%. The median overall survival of all patients was not reached, while 2-years OS was 76.5%. CONCLUSION: Neoadjuvant FOLFIRINOX followed by CRT for middle and lower rectal cancer is feasible, tolerable with satisfactory sphincter preservation rate.
format Online
Article
Text
id pubmed-7568879
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-75688792020-10-30 Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer Sakr, Amr Elsherbeiny, Mamdouh Moneim, Rabab Abdel Shaaban, Saeed Aldaly, Moustafa Asian Pac J Cancer Prev Research Article OBJECTIVE: Neoadjuvant concomitant chemoradiotherapy followed by surgical resection is the standard of care in the treatment of rectal cancer. We are investigating the value of adding combination chemotherapy oxaliplatin, irinotecan, leucovorin and fluorouracil (FOLFIRINOX) before neoadjuvant chemoradiotherapy. METHODS: Forty-one patients with middle and lower rectal cancer were included. FOLFORINOX were given every 2 weeks over 2 months (4 cycles) followed by concomitant chemoradiotherapy (CRT). Surgery was done 6-8 weeks after CRT and then adjuvant 4 months of FOLFOX or XELOX were given. The primary end point was sphincter preservation rate. RESULTS: All patients received the four cycles of neoadjuvant chemotherapy FOLFORINOX, 38 patients completed CRT and only 29 patients underwent surgery. 32 patients were available for assessment (29 patients who underwent surgery and three patients who refuse surgery because of no evidence of disease by endoscopy, imaging and biopsy). Sphincter preservation was achieved in twenty-one patients (51.2%). Pathological complete response rate was 24.1%. After a median follow up of 24 months. Median PFS was 20 months and 2-years PFS was 62.3%. The median overall survival of all patients was not reached, while 2-years OS was 76.5%. CONCLUSION: Neoadjuvant FOLFIRINOX followed by CRT for middle and lower rectal cancer is feasible, tolerable with satisfactory sphincter preservation rate. West Asia Organization for Cancer Prevention 2020-06 /pmc/articles/PMC7568879/ /pubmed/32592369 http://dx.doi.org/10.31557/APJCP.2020.21.6.1717 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sakr, Amr
Elsherbeiny, Mamdouh
Moneim, Rabab Abdel
Shaaban, Saeed
Aldaly, Moustafa
Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer
title Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer
title_full Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer
title_fullStr Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer
title_full_unstemmed Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer
title_short Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer
title_sort neoadjuvant folfirinox followed by chemoradiotherapy for middle and lower rectal cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568879/
https://www.ncbi.nlm.nih.gov/pubmed/32592369
http://dx.doi.org/10.31557/APJCP.2020.21.6.1717
work_keys_str_mv AT sakramr neoadjuvantfolfirinoxfollowedbychemoradiotherapyformiddleandlowerrectalcancer
AT elsherbeinymamdouh neoadjuvantfolfirinoxfollowedbychemoradiotherapyformiddleandlowerrectalcancer
AT moneimrabababdel neoadjuvantfolfirinoxfollowedbychemoradiotherapyformiddleandlowerrectalcancer
AT shaabansaeed neoadjuvantfolfirinoxfollowedbychemoradiotherapyformiddleandlowerrectalcancer
AT aldalymoustafa neoadjuvantfolfirinoxfollowedbychemoradiotherapyformiddleandlowerrectalcancer